We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
Note: As a result of the current COVID-19 (Coronavirus) restrictions, research sites may incorrectly be listed as recruiting or be delayed in responding to patient inquiries due to possible closures. It is suggested that interested patients awaiting a response or current study patients can contact the research site at the phone number provided to ask about study status or confirm scheduled appointments before arriving. Read more about BMS's response to COVID-19 at www.BMS.com.
Jump to Studies
We are currently investigating experimental medications for several autoimmune diseases. Answer a few questions below to see if there are clinical trials that might be right for you.
Thank you for Considering a Clinical Trial
Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).
Here are some options for you to find more information:
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
View Trial DetailsSafety and Efficacy of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
View Trial DetailsAn Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus
View Trial DetailsLong-Term Safety and Efficacy Study of BMS-986165 in Participants With Systemic Lupus Erythematosus
View Trial DetailsAn Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
View Trial DetailsStudy to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Get updates on autoimmune diseases clinical trials
Bristol Myers Squibb is not affiliated with nor endorses any of the listed organizations. The information/links provided by Bristol Myers Squibb are meant for informational purposes only and are not meant to replace a physician's medical advice or imply endorsement.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information